FDA approves larotrectinib for solid tumors with NTRK gene fusions
On November 26, 2018, the Food and Drug Administration granted accelerated approval to larotrectinib (VITRAKVI, Loxo Oncology Inc. and Bayer) for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mu
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: FDA Source Type: news
More News: Brain | Cancer & Oncology | Drugs & Pharmacology | Food and Drug Administration (FDA) | Genetics | Neurology | Pediatrics